Notaristefani Carlo De Net Worth

The estimated Net Worth of Notaristefani Carlo De is at least 308 千$ dollars as of 12 February 2019. Notaristefani De owns over 5,041 units of Teva- Pharmaceutical Industries stock worth over 217,675$ and over the last 7 years Notaristefani sold TEVA stock worth over 90,133$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Notaristefani De TEVA stock SEC Form 4 insiders trading

Notaristefani has made over 1 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently Notaristefani sold 5,041 units of TEVA stock worth 90,133$ on 12 February 2019.

The largest trade Notaristefani's ever made was selling 5,041 units of Teva- Pharmaceutical Industries stock on 12 February 2019 worth over 90,133$. On average, Notaristefani trades about 840 units every 0 days since 2018. As of 12 February 2019 Notaristefani still owns at least 12,120 units of Teva- Pharmaceutical Industries stock.

You can see the complete history of Notaristefani De stock trades at the bottom of the page.

What's Notaristefani De's mailing address?

Notaristefani's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET, PETACH TIKVA, L3, 4951033.

Insiders trading at Teva- Pharmaceutical Industries

Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over 31,332,399$ worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth 16,473,820$ . The most active insiders traders include Sol J Barer、Tal Zvi Zaks、Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of 636,538$. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth 231,181$.

What does Teva- Pharmaceutical Industries do?

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Complete history of Notaristefani De stock trades at Teva- Pharmaceutical Industries

Teva- Pharmaceutical Industries executives and stock owners

Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:

• Kaare Schultz,
  President, Chief Executive Officer, Director
• Kare Schultz,
  Pres, CEO & Director
• Mark Sabag,
  Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
• Hafrun Fridriksdottir,
  Executive Vice President - Global R&D
• Brendan O'Grady,
  Executive Vice President - North America Commercial
• Gianfranco Nazzi,
  Executive Vice President - International Markets Commercial
• Dr. Hafrun Fridriksdottir,
  Exec. VP of Global R&D
• Gianfranco Nazzi,
  Exec. VP of International Markets Commercial
• Eric Drape,
  Exec. VP of Global Operations
• Eliyahu Sharon Kalif,
  Exec. VP & CFO
• Sol Barer,
  Independent Chairman of the Board
• Nechemia Peres,
  Independent Director
• Gerald Lieberman,
  Independent Director
• Amir Elstein,
  Independent Director
• Roberto Mignone,
  Independent Director
• Rosemary Crane,
  Independent Director
• Jean-Michel Halfon,
  Independent Director
• Perry Nisen,
  Independent Director
• Ronit Satchi-Fainaro,
  Independent Director
• Eliyahu Kalif,
  Chief Financial Officer, Executive Vice President
• Kevin Mannix,
  Senior Vice President, Investor Relations
• Janet Vergis,
  Independent Director
• Abbas Hussain,
  Independent Director
• David Stark,
  Executive Vice President, Chief Legal Officer
• Eric Drape,
  Executive Vice President - Global Operations
• Sven Dethlefs,
  Executive Vice President - Global Marketing & Portfolio
• Richard Daniell,
  Executive Vice President - European Commercial
• Eli Shani,
  Exec. VP of Global Marketing & Portfolio
• Galia Inbar,
  Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG
• David M. Stark,
  Exec. VP & Chief Legal Officer
• Amir Weiss,
  Sr. VP & Chief Accounting Officer
• Lori Queisser,
  Sr. VP & Global Compliance Officer
• Andrew J. Weil CPA,
  Chief Accounting Officer
• Eric Drapé,
  Exec. VP of Global Operations
• Iris Beck Codner,
  EVP Global Brand&Communication
• Kare Schultz,
  President and CEO
• Michael James Mc Clellan,
  EVP, Chief Financial Officer
• Notaristefani Carlo De,
  Executive VP Global Operations
• Placid Jover,
  See "Remarks"
• Deborah A Griffin,
  Chief Accounting Officer
• Varda Shalev,
  
• Dan S Suesskind,
  Director
• Murray A Goldberg,
  Director
• Dov Bergwerk,
  Acting Chief Legal Officer
• David R. Mc Avoy,
  EVP, Chief Legal Officer
• Andrew Weil,
  Chief Accounting Officer
• Galia Inbar,
  See "Remarks"
• Eli Shani,
  EVP,Global Marketing&Portfolio
• Angus Grant,
  EVP, Business Development
• Eric A Hughes,
  See "Remarks"
• Vikki L Conway,
  See "Remarks"
• Christine Fox,
  EVP, Head of U.S. Commercial
• Amir Weiss,
  Chief Accounting Officer
• Richard D Francis,
  President and CEO
• Matthew Shields,
  EVP, Global Operations
• Tal Zvi Zaks,